Callio Therapeutics Presents Dual-Payload Antibody-Drug Conjugate
By Daniella Parra Callio Therapeutics presented preclinical data at AACR that supports the first dual-payload antibody drug conjugate in Phase 1 for HER2-expressing cancers. While approved ADC drugs like Enhertu work initially, treatment resistance builds over time because of its...